According to GlobalData, the worldwide thrombectomy device market was worth $2.96 billion in 2024 and is set to register a ...

The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...

花旗更新后的财务模型考虑了Inari对Stryker业绩的预期贡献。预计Inari在2025年约10个月期间将产生5.9亿美元的收入。尽管预计Inari将使Stryker的营业利润率降低0-20基点，但预计也将为每股收益（EPS）增加0.20至0.30美元。

Citi resumed coverage of Stryker (SYK) with a Buy rating and $450 price target following the close of the Inari acquisition tryker has built a ...

If you are looking for growth stocks, the medical device sector is a promising one to start your search. The post Growth ...

Stryker has completed its $4.9 billion acquisition of Inari Medical, a company specializing in venous thromboembolism ...

Powered by rapid AI advancements, enhanced automation processes, and growing demand for commercial adoption, modern robotics ...

Inari’s expertise combined with Stryker’s existing distribution and logistics network could boost volume and procedure ...

Stryker Corp. yesterday closed on its $4.9 billion acquisition of Inari Medical Inc., which is now a wholly owned subsidiary ...

Stryker entered a definitive agreement to acquire all issued and outstanding shares of Inari Medical's common stock. Stryker ...

2025年2月19日，史赛克（Stryker）正式宣布完成了对Inari Medical的收购。此前，史赛克已宣布达成了一项价值49亿美元（折合360亿人民币）的交易，旨在收购这家专注于静脉血栓栓塞（VTE）治疗的公司。

Stryker announced that it has completed the acquisition of Inari Medical, Inc., a provider of solutions for venous thromboembo ...